SAP revises non-financial KPIs, introduces Business Health Culture Index

Christian Klein Chief Executive Officer (CEO) SAP SE
Christian Klein Chief Executive Officer (CEO) - SAP SE
0Comments

SAP SE has announced changes to its non-financial key performance indicators (KPIs), which are linked to the compensation of the Executive Board. The company will replace its guidance for Women in Executive Roles with the Business Health Culture Index (BHCI). This index, based on employee engagement survey results, has been tracked by SAP since 2009. For 2025, SAP anticipates a BHCI score between 80% and 82%.

The other non-financial KPIs will remain unchanged. In 2025, SAP expects a Customer Net Promoter Score ranging from 12 to 16 and an Employee Engagement Index between 74% and 78%. Additionally, the company aims to continue reducing carbon emissions across its value chain.

SAP emphasizes its commitment to fostering an inclusive workplace where all employees have equal opportunities and assures compliance with legal requirements in every country it operates.

For further information, visit the SAP News Center or follow updates on LinkedIn and Bluesky.

Media inquiries can be directed to Joellen Perry at +1 (626) 265-0370 or [email protected]; Bridget Carroll at +1 (267) 615-3589 or [email protected]; Daniel Reinhardt at +49 6227 7-40201 or [email protected]; or contact the SAP Press Room at [email protected].



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.